Publication date: Available online 7 November 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Corrado Pelaia, Cecilia Calabrese, Sarah Barbuto, Maria Teresa Busceti, Mariaimmacolata Preianò, Luca Gallelli, Rocco Savino, Alessandro Vatrella, Girolamo PelaiaAbstractOmalizumab is a humanized monoclonal antibody which binds to human immunoglobulins E (IgE), thus preventing their interactions with both high affinity and low affinity IgE receptors. Therefore, omalizumab is currently recommended for add-on biological therapy of uncontrolled allergic asthma, mainly characterized by type 2 airway eosinophilic inflammation. Because omalizumab has been the first, and for a long time the only available monoclonal antibody for add-on treatment of type 2 asthma, some long-term studies have ...
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2SXCIeH
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.